The roughly $2.1 trillion tech IPO pipeline that Forge Global has tracked through 2026 hasn't shrunk meaningfully as the year's volatility has piled up -- it has deferred. Companies that were reportedly IPO-ready earlier this year are choosing to wait for cleaner market windows rather than withdrawing S-1 registrations outright, a fundamentally different pattern than 2022's outright IPO freeze, when the pipeline genuinely emptied as companies pulled filings and postponed indefinitely.
This week supplied two fresh, concrete reasons for continued deferral rather than a rush to list. First, Tesla and Alphabet's capex-driven selloff spread into Asian markets, delivering the worst trading session in over a year for megacap tech and a reminder that public investors have grown newly intolerant of open-ended AI infrastructure spending even from companies with genuinely strong underlying fundamentals. Second, Alphabet's disclosure of its first-ever negative free-cash-flow quarter gave public-market investors a concrete, citable data point that even the best-capitalized companies in tech are running negative cash flow to fund AI buildout -- exactly the kind of scrutiny any newly public, AI-adjacent company should expect to face on its very first earnings call as a public entity.
SpaceX's shares trading below their IPO price is the case study every late-stage private company's board is now studying before committing to a listing date. SpaceX was, by almost any measure, the most anticipated and best-positioned IPO candidate of the past several years -- a category-defining company with genuine revenue, a dominant market position, and years of pent-up investor demand. That it has still traded below its IPO price demonstrates that even the strongest possible IPO candidate isn't immune to listing into a capex-anxious market, which is exactly the risk every board weighing timing right now is trying to avoid.
“Meanwhile, CXMT's $8.6 billion Shanghai listing this week is proof the IPO market isn't closed -- it's selective and geographically uneven.”
Meanwhile, CXMT's $8.6 billion Shanghai listing this week is proof the IPO market isn't closed -- it's selective and geographically uneven. Capital is still flowing into large offerings where investors have high conviction in near-term demand and clear strategic positioning, particularly in China's semiconductor self-sufficiency push. That's a different bar than "the market is open" broadly; it's a bar of "the market is open for specific, well-positioned stories," and most of the deferred U.S. tech pipeline doesn't currently meet it.
The quality gap between IPO-ready companies that could list into current conditions and companies still waiting for a cleaner window keeps widening as a result. Companies with strong unit economics, clear paths to profitability and defensible market positions retain optionality to list opportunistically -- as Scribe Therapeutics demonstrated with its upsized, top-of-range biotech offering. Companies with heavier capital intensity or less mature unit economics face a much higher bar to convince public investors they're a good match for a market this newly skeptical of capex-heavy growth stories.
The bear case for this framework: deferral isn't free. Every quarter a company stays private past its natural IPO readiness window extends the liquidity wait for employees and early investors, and pipeline value estimates like Forge's $2.1 trillion figure are necessarily speculative, based on private valuation marks that may not hold once companies actually test public-market pricing. A pipeline that looks large on paper can shrink quickly in practice once companies that finally do list get repriced sharply lower than their last private round.
Watch whether any large, well-positioned private company breaks the deferral pattern and lists successfully into current conditions in the next quarter, whether Google Cloud's 82% revenue growth is enough to keep AI-adjacent IPO candidates' stories credible despite the negative-FCF headline, and whether SpaceX's stock recovers back above its IPO price in a way that would meaningfully change the risk calculus for the rest of the deferred pipeline.
